Arcellx, Inc. (ACLX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Redwood City, MD, United States. वर्तमान CEO हैं Rami Elghandour.
ACLX के पास है IPO तिथि 2022-02-04, 163 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $6.73B.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for patients with cancer and other serious diseases. The company's lead candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, while its pipeline includes ACLX-001, a dual-targeting immunotherapy combining ARC-T cells and SparX proteins, as well as additional programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Founded in 2014 and headquartered in Gaithersburg, Maryland, Arcellx focuses on advancing next-generation cell and protein-based therapies to address unmet medical needs in oncology.
